{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T13:58:45Z","timestamp":1764079125280},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2015,11,10]],"date-time":"2015-11-10T00:00:00Z","timestamp":1447113600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1038\/bjc.2015.343","type":"journal-article","created":{"date-parts":[[2015,11,10]],"date-time":"2015-11-10T21:01:34Z","timestamp":1447189294000},"page":"1534-1540","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["A phase I combination dose-escalation study of eribulin mesylate and gemcitabine in patients with advanced solid tumours: a study of the Princess Margaret Consortium"],"prefix":"10.1038","volume":"113","author":[{"given":"S","family":"Lheureux","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A M","family":"Oza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S A","family":"Laurie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"Halford","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D","family":"Jonker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D","family":"Keller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V","family":"Bourade","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L","family":"Doyle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L L","family":"Siu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"Goel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,11,10]]},"reference":[{"issue":"3","key":"BFbjc2015343_CR1","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1097\/00001813-199803000-00001","volume":"9","author":"MS Aapro","year":"1998","unstructured":"Aapro MS, Martin C, Hatty S (1998) Gemcitabine--a safety review. Anticancer Drugs 9 (3): 191\u2013201.","journal-title":"Anticancer Drugs"},{"issue":"8","key":"BFbjc2015343_CR2","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1200\/JCO.1994.12.8.1535","volume":"12","author":"RP Abratt","year":"1944","unstructured":"Abratt RP, Bezwoda WR, Falkson G, Goedhals L, Hacking D, Rugg TA (1944) Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a phase II study. J Clin Oncol 12 (8): 1535\u20131540.","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"BFbjc2015343_CR3","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1136\/ijgc-00009577-200505001-00003","volume":"15","author":"MA Bookman","year":"2005","unstructured":"Bookman MA (2005) Gemcitabine monotherapy in recurrent ovarian cancer: from the bench to the clinic. Int J Gynecol Cancer 15 (Suppl 1): 12\u201317.","journal-title":"Int J Gynecol Cancer"},{"issue":"1","key":"BFbjc2015343_CR4","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/bjc.1996.18","volume":"73","author":"J Carmichael","year":"1996","unstructured":"Carmichael J, Fink U, Russell RC, Spittle MF, Harris AL, Spiessi G, Blatter J (1996) Phase II study of gemcitabine in patients with advanced pancreatic cancer. Br J Cancer 73 (1): 101\u2013105.","journal-title":"Br J Cancer"},{"issue":"9769","key":"BFbjc2015343_CR5","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/S0140-6736(11)60070-6","volume":"377","author":"J Cortes","year":"2011","unstructured":"Cortes J, O'Shaughnessy J, Loesch D, Blum JL, Vahdat LT, Petrakova K, Chollet P, Manikas A, Di\u00e9ras V, Delozier T, Vladimirov V, Cardoso F, Koh H, Bougnoux P, Dutcus CE, Seegobin S, Mir D, Meneses N, Wanders J, Twelves C EMBRACE (Eisai Metastatic Breast Cancer Study Assessing Physician's Choice Versus E7389) investigators (2011) Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet 377 (9769): 914\u2013923.","journal-title":"Lancet"},{"issue":"6","key":"BFbjc2015343_CR6","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1124\/mol.106.026641","volume":"70","author":"DA Dabydeen","year":"2006","unstructured":"Dabydeen DA, Burnett JC, Bai R, Verdier-Pinard P, Hickford SJ, Pettit GR, Blunt JW, Munro MH, Gussio R, Hamel E (2006) Comparison of the activities of the truncated halichondrin B analog NSC 707389 (E7389) with those of the parent compound and a proposed binding site on tubulin. Mol Pharmacol 70 (6): 1866\u20131875.","journal-title":"Mol Pharmacol"},{"issue":"1","key":"BFbjc2015343_CR7","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1093\/annonc\/mdh031","volume":"15","author":"U Gatzemeier","year":"2004","unstructured":"Gatzemeier U, Groth G, Butts C, Van Zandwijk N, Shepherd F, Ardizzoni A, Barton C, Ghahramani P, Hirsh V (2004) Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer. Ann Oncol 15 (1): 19\u201327.","journal-title":"Ann Oncol"},{"issue":"Pt A","key":"BFbjc2015343_CR8","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.neuropharm.2013.08.016","volume":"76","author":"E Gornstein","year":"2014","unstructured":"Gornstein E, Schwarz TL (2014) The paradox of paclitaxel neurotoxicity: Mechanisms and unanswered questions. Neuropharmacology 76 (Pt A): 175\u2013183.","journal-title":"Neuropharmacology"},{"issue":"7","key":"BFbjc2015343_CR9","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1158\/1535-7163.MCT-04-0345","volume":"4","author":"MA Jordan","year":"2005","unstructured":"Jordan MA, Kamath K, Manna T, Okouneva T, Miller HP, Davis C, Littlefield BA, Wilson L (2005) The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth. Mol Cancer Ther 4 (7): 1086\u20131095.","journal-title":"Mol Cancer Ther"},{"issue":"12","key":"BFbjc2015343_CR10","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.1038\/bjc.2014.554","volume":"111","author":"M Koczywas","year":"2014","unstructured":"Koczywas M, Frankel PH, Synold TW, Lenz HJ, Mortimer JE, El-Khoueiry AB, Gandara DR, Cristea MC, Chung VM, Lim D, Reckamp KL, Lau DH, Doyle LA, Ruel C, Carroll MI, Newman EM (2014) Phase I study of the halichondrin B analogue eribulin mesylate in combination with cisplatin in advanced solid tumors. Br J Cancer 111 (12): 2268\u20132274.","journal-title":"Br J Cancer"},{"issue":"16","key":"BFbjc2015343_CR11","doi-asserted-by":"publisher","first-page":"5760","DOI":"10.1158\/0008-5472.CAN-04-1169","volume":"64","author":"G Kuznetsov","year":"2004","unstructured":"Kuznetsov G, Towle MJ, Cheng H, Kawamura T, TenDyke K, Liu D, Kishi Y, Yu MJ, Littlefield BA (2004) Induction of morphological and biochemical apoptosis following prolonged mitotic blockage by halichondrin B macrocyclic ketone analog E7389. Cancer Res 64 (16): 5760\u20135766.","journal-title":"Cancer Res"},{"issue":"5","key":"BFbjc2015343_CR12","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1158\/1535-7163.MCT-08-1026","volume":"8","author":"G Kuznetsov","year":"2009","unstructured":"Kuznetsov G, Xu Q, Rudolph-Owen L, Tendyke K, Liu J, Towle M, Zhao N, Marsh J, Agoulnik S, Twine N, Parent L, Chen Z, Shie JL, Jiang Y, Zhang H, Du H, Boivin R, Wang Y, Romo D, Littlefield BA (2009) Potent in vitro and in vivo anticancer activities of des-methyl, des-amino pateamine A, a synthetic analogue of marine natural product pateamine A. Mol Cancer Ther 8 (5): 1250\u20131260.","journal-title":"Mol Cancer Ther"},{"issue":"4","key":"BFbjc2015343_CR13","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1038\/sj.bjc.6600780","volume":"88","author":"V Lorusso","year":"2003","unstructured":"Lorusso V, Crucitta E, Silvestris N, Catino A, Caporusso L, Mazzei A, Guida M, Latorre A, Sambiasi D, D'Amico C, Schittulli F, Calabrese P, De Lena M (2003) Phase I\/II study of gemcitabine plus mitoxantrone as salvage chemotherapy in metastatic breast cancer. Br J Cancer 88 (4): 491\u2013495.","journal-title":"Br J Cancer"},{"issue":"2","key":"BFbjc2015343_CR14","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1245\/s10434-012-2767-7","volume":"20","author":"GC Mattiucci","year":"2013","unstructured":"Mattiucci GC, Ippolito E, D'Agostino GR, Alfieri S, Antinori A, Crucitti A, Balducci M, Deodato F, Luzi S, Macchia G, Smaniotto D, Morganti AG, Valentini V (2013) Long-term analysis of gemcitabine-based chemoradiation after surgical resection for pancreatic adenocarcinoma. Ann Surg Oncol 20 (2): 423\u2013429.","journal-title":"Ann Surg Oncol"},{"issue":"Suppl 5","key":"BFbjc2015343_CR15","doi-asserted-by":"publisher","first-page":"v7","DOI":"10.1093\/annonc\/mdj941","volume":"17","author":"E Mini","year":"2006","unstructured":"Mini E, Nobili S, Caciagli B, Landini I, Mazzei T (2006) Cellular pharmacology of gemcitabine. Ann Oncol 17 (Suppl 5): v7\u201312.","journal-title":"Ann Oncol"},{"issue":"7","key":"BFbjc2015343_CR16","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1158\/1535-7163.MCT-08-0095","volume":"7","author":"T Okouneva","year":"2008","unstructured":"Okouneva T, Azarenko O, Wilson L, Littlefield BA, Jordan MA (2008) Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase. Mol Cancer Ther 7 (7): 2003\u20132011.","journal-title":"Mol Cancer Ther"},{"issue":"4 Suppl 11","key":"BFbjc2015343_CR17","first-page":"3","volume":"22","author":"W Plunkett","year":"1995","unstructured":"Plunkett W, Huang P, Xu YZ, Heinemann V, Grunewald R, Gandhi V (1995) Gemcitabine: metabolism, mechanisms of action, and self-potentiation. Semin Oncol 22 (4 Suppl 11): 3\u201310.","journal-title":"Semin Oncol"},{"issue":"6","key":"BFbjc2015343_CR18","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1586\/14737140.2014.920693","volume":"14","author":"L Polastro","year":"2014","unstructured":"Polastro L, Aftimos PG, Awada A (2014) Eribulin Mesylate in the management of metastatic breast cancer and other solid cancers: a drug review. Expert Rev Anticancer Ther 14 (6): 649\u2013665.","journal-title":"Expert Rev Anticancer Ther"},{"issue":"Suppl","key":"BFbjc2015343_CR19","doi-asserted-by":"publisher","first-page":"Abstr LBA10502","DOI":"10.1200\/jco.2015.33.18_suppl.lba10502","volume":"33","author":"P Sch\u00f6ffski","year":"2015","unstructured":"Sch\u00f6ffski P, Maki RG, Italiano A, Gelderblom H, Grignani G, Pires De Camargo V, Bauer S, Young Rha S, Chawla SP, Blay JY, Hohenberger P, D'Adamo DR, Wang B, Chmielowski B, Le Cesne A, Demetri GD, Patel S (2015) Randomized, open-label, multicenter, phase III study of eribulin versus dacarbazine in patients (pts) with leiomyosarcoma (LMS) and adipocytic sarcoma (ADI). J Clin Oncol 33 (Suppl): Abstr LBA10502.","journal-title":"J Clin Oncol"},{"issue":"11","key":"BFbjc2015343_CR20","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1016\/S1470-2045(11)70230-3","volume":"12","author":"P Sch\u00f6ffski","year":"2011","unstructured":"Sch\u00f6ffski P, Ray-Coquard IL, Cioffi A, Bui NB, Bauer S, Hartmann JT, Krarup-Hansen A, Gr\u00fcnwald V, Sciot R, Dumez H, Blay JY, Le Cesne A, Wanders J, Hayward C, Marreaud S, Ouali M, Hohenberger P European Organisation for Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group (STBSG) (2011) Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes. Lancet Oncol 12 (11): 1045\u20131052.","journal-title":"Lancet Oncol"},{"issue":"1","key":"BFbjc2015343_CR21","doi-asserted-by":"publisher","first-page":"12","DOI":"10.4048\/jbc.2013.16.1.12","volume":"16","author":"A Shablak","year":"2013","unstructured":"Shablak A (2013) Eribulin for advanced breast cancer: a drug evaluation. J Breast Cancer 16 (1): 12\u201315.","journal-title":"J Breast Cancer"},{"issue":"2","key":"BFbjc2015343_CR22","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.critrevonc.2011.03.002","volume":"81","author":"U Swami","year":"2012","unstructured":"Swami U, Chaudhary I, Ghalib MH, Goel S (2012) Eribulin -a review of preclinical and clinical studies. Crit Rev Oncol Hematol 81 (2): 163\u2013184.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"8","key":"BFbjc2015343_CR23","doi-asserted-by":"publisher","first-page":"5016","DOI":"10.3390\/md13085016","volume":"13","author":"U Swami","year":"2015","unstructured":"Swami U, Shah U, Goel S (2015) Eribulin in cancer treatment. Mar Drugs 13 (8): 5016\u20135058.","journal-title":"Mar Drugs"},{"issue":"3","key":"BFbjc2015343_CR24","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92 (3): 205\u2013216.","journal-title":"J Natl Cancer Inst"},{"key":"BFbjc2015343_CR25","unstructured":"Towle MJ, Agoulnik S, Kuznetsov G, TenDyke K, Reardon C, Cheng H, Zheng W, Seletsky BM, Palme MH, Kishi Y, Lewis MD, Yu MJ, Littlefield BA (2003) In vivo efficacy of E7389, a synthetic analogue of the marine sponge antitubulin agent halichondrin B, against human tumor xenografts under monotherapy and combination therapy conditions. Proc Am Assoc Cancer Res (AACR) 44 (2nd ed.) Abstract 2749."},{"issue":"3","key":"BFbjc2015343_CR26","first-page":"1013","volume":"61","author":"MJ Towle","year":"2001","unstructured":"Towle MJ, Salvato KA, Budrow J, Wels BF, Kuznetsov G, Aalfs KK, Welsh S, Zheng W, Seletsky BM, Palme MH, Habgood GJ, Singer LA, Dipietro LV, Wang Y, Chen JJ, Quincy DA, Davis A, Yoshimatsu K, Kishi Y, Yu MJ, Littlefield BA (2001) In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B. Cancer Res 61 (3): 1013\u20131021.","journal-title":"Cancer Res"},{"issue":"suppl 5","key":"BFbjc2015343_CR27","doi-asserted-by":"publisher","first-page":"Abstract 273","DOI":"10.1200\/jco.2012.30.5_suppl.273","volume":"30","author":"N Vogelzang","year":"2012","unstructured":"Vogelzang N, Conkling P, Duran I, Maroto J, Modiano M, De Leonardis P, Hodge JP, Lieberman R (2012) Phase Ib\/II study of eribulin mesylate administered in combination with gemcitabine\/cisplatin as first-line therapy for locally advanced or metastatic bladder cancer: Phase Ib results. J Clin Oncol 30 (suppl 5): Abstract 273.","journal-title":"J Clin Oncol"},{"issue":"17","key":"BFbjc2015343_CR28","doi-asserted-by":"publisher","first-page":"3068","DOI":"10.1200\/JCO.2000.18.17.3068","volume":"18","author":"H Von der Maase","year":"2000","unstructured":"Von der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore MJ, Bodrogi I, Albers P, Knuth A, Lippert CM, Kerbrat P, Sanchez Rovira P, Wersall P, Cleall SP, Roychowdhury DF, Tomlin I, Visseren-Grul CM, Conte PF (2000) Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 18 (17): 3068\u20133077.","journal-title":"J Clin Oncol"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/bjc2015343.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/bjc2015343","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/bjc2015343.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T13:30:32Z","timestamp":1684416632000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bjc2015343"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11,10]]},"references-count":28,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["BFbjc2015343"],"URL":"https:\/\/doi.org\/10.1038\/bjc.2015.343","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,11,10]]},"assertion":[{"value":"29 April 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2015","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2015","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2015","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}